Drug combo aims to control Slow-Growing lymphoma without chemo

NCT ID NCT01316523

Terminated Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily for three weeks out of four, plus rituximab infusions, and the study measured how many patients responded to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide and rituximab
What this could lead to: If successful, this combination could offer a chemotherapy-free option to control indolent non-Hodgkin's lymphoma and delay the need for more aggressive treatment.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited. Lenalidomide can cause serious side effects like blood clots and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICLE CELL LYMPHOMA, GRADE I OR II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma indolent B-cell non-Hodgkin lymphoma marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

Sutter Pacific Medical Foundation

Santa Rosa, California, 95403, United States
University of California Davis Cancer Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.